the future of cardiovascular implantable devices
A free repsonsive template by webflow
The next generation of vascular grafts with first-in-class features for children and adults
Learn moreSolving the problems of today's heart valves with tomorrow's polymeric leaflets
Learn more
Our polymeric material platform enables new functionalities without compromising performance and usability
The only vascular graft on the market to provide radiopaque indicators to enable advanced noninvasive visualization
Thousands of implants to date with excellent results underscore PECA's commitment to patient safety
Pre-implant customization allows for flaring and tapering for anatomical match and improved hemodynamics
Controllable expandability post-implant can provide growth potential and help relieve stenosis
Radiopaque indicators provide advanced noninvasive visualization not available in other polymeric grafts
Our proprietary polymer material platform provides a highly bio-inert surface to reduce thrombosis and hyperplasia
Our polymer platform provides a bio-inert surface inherent to the material, without pharmaceutical coatings that wear off
Our polymeric material platform enables new functionalities without compromising performance and usability
Our polymeric material platform enables new functionalities without compromising performance and usability
MASA Valve features a proprietary bi-leaflet valve designed for the unique anatomy of pulmonary reconstruction
MASA Valve is being evaluated in a prospective USA clinical trial, with first-in-human implant complete. MASA Valve is restricted by USA law to investigational use only.
Our polymeric material platform enables new functionalities without compromising performance and usability
Fully-polymeric leaflets enable a slimmed-down delivery system to reduce the chance vascular injury
STEALTH utilizes our clinically-proven polymer material platform, providing excellent performance and durability
Co-Founder
Forbes 30 Under 30
Carnegie Mellon MechE & BioE
Co-Founder
Pediatric Surgeon
Carnegie Mellon BioE
Co-Founder
Forbes 30 Under 30
Carnegie Mellon Business
Founding Chairman, Dept. Surgery at Cooper
Chief of Surgery at Cooper U Healthcare
Serial Entrepreneur & Inventor
Tech Sold to Edwards, Terumo, Cook
Serial Entrepreneur, >5 Exits / IPOs
Managing Director of Runway Healthcare
CEO at Embrella through sale to Edwards
Fmr. Board Chairman at Endologix
Managing Partner at Gravitas Healthcare
Fmr. Managing Director at Cowen & Co.
Fmr. Manager of. Galleon Healthcare Fund
Wharton MBA, Stanford MS
Managing Partner at Allegheny Financial Group
Managing Partner at Allegheny Investments
Certified Financial Planner
Named Who's Who in America Finance & Industry
Co-Founder of LaunchCyte
Serial Entrepreneur
Fmr. Director Pitt Big Idea Center
Fmr. Prof. Entrepreneurship at Carnegie Mellon
Managing Partner at Allegheny Financial Group
Named 40 Under 40 Investment Advisors
Certified Financial Planner
Managing Partner at Allegheny Investments
Member of Blue Tree Allied Capital
Fmr. Fedex Services Sales Officer
Serial Sales and Logistics Executive
Thee Decades in Ops, Sales and Supply Chain
Co-Founder & CEO of PECA Labs
Congenital Defect Survivor
Forbes 30 Under 30
Carnegie Mellon MechE & BioE
Co-Founder
Forbes 30 Under 30
Carnegie Mellon MechE & BioE
Co-Founder
Pediatric Surgeon
Carnegie Mellon BioE
Co-Founder
Forbes 30 Under 30
Carnegie Mellon Business
Co-Founder
Forbes 30 Under 30
Carnegie Mellon MechE & BioE
Co-Founder
Pediatric Surgeon
Carnegie Mellon BioE
Co-Founder
Forbes 30 Under 30
Carnegie Mellon Business
June 2023 - Children’s Hospital of Philadelphia, a world-renowned children’s hospital and research institute, became the first site in the world to implant a MASA Valve in a pediatric patient. This marks a significant milestone in PECA Labs’ mission to bring the first polymeric pulmonary valve to market and improve outcomes for patients.
May 2023 - PECA Labs has announced it has added Dr. Jeffrey P. Carpenter, Jeffrey O’Donnell, Sr. and Samuel E. Navarro to its board of directors. The new board members will help guide the company as it develops and commercializes cardiovascular implants based on its novel tunable polymeric material platform.
April 2023 - PECA Labs announced the U.S. Food and Drug Administration (FDA) granted an Investigational Device Exemption (IDE) for an early feasibility study (EFS) of its MASA Valve. The MASA Valve is a polymeric valved conduit for pulmonary valve reconstruction. The company has begun enrollment for the study at five clinical sites across the U.S.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique.
Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat.
Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique.
Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat.
Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique.
Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat.
Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
Founded by a group Carnegie Mellon alumni including a pediatric surgeon, PECA Labs is revolutionizing cardiovascular implantable devices with a polymer platform and a novel design approach.
